In the aging populations, the gap between average life expectancy and healthy life expectancy is not closing, and controlling ever-increasing health care costs is becoming important social challenges. Pharmaceuticals have made a significant contribution to the treatment of lifestyle-related diseases and other chronic diseases such as diabetes and cardiovascular diseases. For now, the role of pharmaceuticals is not only providing such treatment but also “preventing disease” and “limiting the severity of disease” is becoming much more important.
Solutions for disease management and prevention from disease progression based on scientific evidence utilizing digital technology and medical big data, which have been rapidly developed and widely accepted in recent years, is expected to contribute to further progress in medical care and potential solutions for social problems.
With Sphere "Chronic Disease Progression Prevention," we aim to prevent the onset and severity of chronic diseases such as lifestyle-related diseases by providing solutions for disease management and prevention of severity based on scientific evidence.
In the short and medium term, we aim to develop and provide exercise programs and services that incorporate gamification (applying game elements to services and systems to improve user motivation and satisfaction) for diabetes and more patient-centric home-healthcare systems or services for preventing cardiovascular diseases progression. Based on the data accumulated through digital devices, we also are working to develop and provide risk prediction and individualized intervention measures through deep learning, which will help lead to disease management and prevention of disease progression according to individual constitution and lifestyle.
In the long term, we aim to prevent the onset of symptoms of the diseases and the progression of severity by highly individualized optimization by developing personalized scientific intervention measures from PHR (Personal Health Record)/EMR (Electronic Medical Record).
Assets and capabilities that Astellas expects from its partners
- Development and manufacturing technology of low invasive while highly precise biosensors or wearable devices
- Development and operation technology of applications with high user adherence
- Development and operation technology of an integrated system to promote utilization of personal health records (PHR) and electronic medical/health records (EMR/EHR).
- Development technology and solutions for novel interventions to prevent the progression of chronic diseases.